Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas

Oncogene

Volumn 32, Issue 25, 2013, Pages 3028-3038

  Wolf, S ^a   Rudolph, C ^a   Morgan, M ^a   Busche G ^a   Salguero, G ^a   Stripecke, R ^a   Schlegelberger, B ^a   Baum, C ^a   Modlich, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Evi1; malignant histiocytosis; murine BMT model; myelomonocytic leukemia; NRas; retroviral vector

Indexed keywords

ASPARTIC ACID; EVI1 PROTEIN; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PRDM16 PROTEIN; PROTEIN KINASE B; PROTEIN N RAS; RAS PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MALIGNANT HISTIOCYTOSIS; MOUSE; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; RAS PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

MURINAE; MUS;

EID: 84879416050     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.329     Document Type: Article

References (67)

1. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990; 348: 125-132.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22
3. COSMIC database http://www.sanger.ac.uk/genetics/CGP/cosmic/.
4. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
5. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
6. Koike K, Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008; 141: 567-575.
7. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96: 1655-1669.
8. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomo-nocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996; 93: 14845-14850.
9. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859-1863.
10. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42: 794-800.
11. Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica 2010; 95: 320-323.
12. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90: 479-488.
13. Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia 2003; 17: 1482-1498.
14. Haupt Y, Harris AW, Adams JM. Retroviral infection accelerates T lymphoma-genesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene 1992; 7: 981-986.
15. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991-6002.
16. MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 1999; 93: 2043-2056.
17. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML-and AML-like diseases in mice. Blood 2006; 108: 2349-2357.
18. Wiesner SM, Jones JM, Hasz DE, Largaespada DA. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood 2005; 106: 1054-1062.
19. Leenen PJ, Melis M, Slieker WA, Van Ewijk W. Murine macrophage precursor characterization. II. Monoclonal antibodies against macrophage precursor antigens. Eur J Immunol 1990; 20: 27-34.
20. Hao X, Fredrickson TN, Chattopadhyay SK, Han W, Qi CF, Wang Z et al. The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice. Vet Pathol 2010; 47: 434-445.
21. Leenen PJ, Bechan GI, Melis M, den Broeder BJ, Lohler J, Egeler RM. Heterogeneity in a mouse model of histiocytosis: transformation of Langerin + dendritic cells, macrophages, and precursors. J Leukoc Biol 2010; 87: 949-958.
22. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002; 41: 1-29.
23. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
24. Takaoka M, Harada H, Deramaudt TB, Oyama K, Andl CD, Johnstone CN et al. Ha-Ras(G12V) induces senescence in primary and immortalized human esopha-geal keratinocytes with p53 dysfunction. Oncogene 2004; 23: 6760-6768.
25. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008; 14: 335-343.
26. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008; 111: 4329-4337.
27. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523-D527.
28. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005; 106: 3932-3939.
29. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
30. De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K et al. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 2011; 154: 337-348.
31. Pradhan AK, Mohapatra AD, Nayak KB, Chakraborty S. Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One 2011; 6: e25370.
32. Modlich U, Bohne J, Schmidt M, von Kalle C, Knob S, Schambach A et al. Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
33. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
34. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514-4518.
35. Diaz R, Lopez-Barcons L, Ahn D, Garcia-Espana A, Yoon A, Matthews J et al. Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis 2004; 25: 535-539.
36. Mangues R, Seidman I, Gordon JW, Pellicer A. Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. Oncogene 1992; 7: 2073-2076.
37. Mangues R, Kahn JM, Seidman I, Pellicer A. An overexpressed N-ras proto-oncogene cooperates with N-methylnitrosourea in mouse mammary carcinogenesis. Cancer Res 1994; 54: 6395-6401.
38. Mangues R, Symmans WF, Lu S, Schwartz S, Pellicer A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumor-igenesis. Oncogene 1996; 13: 1053-1063.
39. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res 2008; 14: 2249-2252.
40. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
41. Cline MJ. Histiocytes and histiocytosis. Blood 1994; 84: 2840-2853.
42. Lohler J, Franz T, Fusco A, Pragnell I, Ostertag W. Murine retrovirus-induced malignant histiocytosis, an experimental model for the disease in humans. Leukemia 1987; 1: 58-68.
43. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436: 660-665.
44. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
45. Wahlers A, Zipfel PF, Schwieger M, Ostertag W, Baum C. In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity. J Virol 2002; 76: 303-312.
46. Wahlers A, Kustikova O, Zipfel PF, Itoh K, Koester M, Heberlein C et al. Upstream conserved sequences of mouse leukemia viruses are important for high trans-gene expression in lymphoid and hematopoietic cells. Mol Ther 2002; 6: 313-320.
47. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
48. Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia 2011; 25: 874-877.
49. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853.
50. Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28: 3890-3898.
51. Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C et al. Over-expression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest 2007; 117: 3696-3707.
52. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011; 117: 2022-2032.
53. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L et al. EVI1 induces myelodys-plastic syndrome in mice. J Clin Invest 2004; 114: 713-719.
54. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 2007; 109: 3998-4005.
55. Cuenco GM, Ren R. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 2004; 23: 569-579.
56. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
57. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, Li Z et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008; 22: 1519-1528.
58. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, Kim HJ et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005; 106: 2530-2533.
59. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 2009; 69: 1633-1642.
60. Gomez-Benito M, Conchillo A, Garcia MA, Vazquez I, Maicas M, Vicente C et al. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. Br J Cancer 103: 1292-1296.
61. Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N et al. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 2011; 96: 1448-1456.
62. Konrad TA, Karger A, Hackl H, Schwarzinger I, Herbacek I, Wieser R. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol 2009; 86: 813-822.
63. Omidvar N, Kogan S, Beurlet S, le Pogam C, Janin A, West R et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007; 67: 11657-11667.
64. Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 2006; 13: 1524-1533.
65. Meyer J, Jucker M, Ostertag W, Stocking C. Carboxyl-truncated STAT5beta is generated by a nucleus-associated serine protease in early hematopoietic rogenitors. Blood 1998; 91: 1901-1908.
66. Schmidt M, Hoffmann G, Wissler M, Lemke N, Mussig A, Glimm H et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther 2001; 12: 743-749.
67. Kustikova OS, Modlich U, Fehse B. Retroviral insertion site analysis in dominant haematopoietic clones. Methods Mol Biol 2009; 506: 373-390.